



H.C. WAINWRIGHT GLOBAL LIFE SCIENCES CONFERENCE

Anthony Fernando, President & CEO
Shameze Rampertab, CFO

March 9, 2021

Forward Looking Statements

This presentation includes statements relating to the Senhance Surgical System's market development and a general corporate update. These statements and other statements regarding our future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, whether the market development activities related to the Senhance Surgical System will be successful, the pace of adoption of our products by surgeons, the success and market opportunity of our products, the impact on the ongoing pandemic on our business and our customers, the effect on our business on existing and new regulatory requirements and other economic and competitive factors and whether we will be able to execute upon our corporate objectives. For a discussion of the risks and uncertainties associated with the Company's business, please review our filings with the Securities and Exchange Commission (SEC). You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this presentation and speak only as of the origination date of this presentation. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.



We believe in digitizing the interface between the surgeon and patient to pioneer a new era of **Performance-Guided Surgery** by unlocking the Clinical Intelligence to enable consistently superior outcomes and a new standard of surgery.

Asensus Surgical (NYSE American:ASXC)

EARLY-COMMERCIAL STAGE COMPANY USHERING IN A NEW ERA OF MINIMALLY INVASIVE SURGERY



Global
Regulatory
Approvals



Global
Training Centers



100+
Active Surgeon
Users



Active
Clinical Sites in
US, EU & Asia



4,000+
Surgeries
Performed



Robust
Intellectual Property
Portfolio



1st
eye-sensing camera control
haptic feedback
3 mm robotic instruments
augmented intelligence and machine vision
real-time surgical image analytics
pediatrics with robotic 3 mm




Strong
Talented Global
Team




Integrated
Remote
Mentoring


Global Market Trends in Surgical Robotics



Worldwide Robotic Penetration Rate is < 5%, Today




SURGICAL ROBOTICS IS A LARGE AND FAST-GROWING MARKET AND CONVERTING LAPAROSCOPIC SURGERY IS A GREENFIELD OPPORTUNITY



The Reality of Surgery


1 in 5 patients undergoing surgery has
1 or more complications*



Overall profit margin decreased from 5.8% for patients without complications to 0.1% for patients with complications.**

Essentially, hospitals make **no money if there is a complication.**

There's Something Missing in the OR



Unintended and preventable surgical complications are rampant and cost health systems billions of dollars each year




Limited technological innovation
(robotics is 20 years old)




Lack of access to critical real-time information

Surgical Decision Chain



Something is Missing



Minimal innovation to improve decision-making aspects in the high-pressure, highly-variable situations that repeatedly occur during surgery.


Sensing, Analyzing and **Deciding** are what **drive surgical outcomes.**

We Should Expect More From Surgery


Holistic approach to addressing each phase of the surgical decision chain

- **Increase safety** for better outcomes which lead to better patient and provider satisfaction
- **Reduce surgical variability** and factors that contribute to poor outcomes
- **Guide surgeons** to successfully navigate when unexpected events occur to effectively reduce surgical errors and complications
- **Provide real-time clinical intelligence** and capabilities to create more predictable outcomes to meet value-based care constraints

Evolution of Surgery



Performance-Guided Surgery



Improved Decision Making

Improved Collaboration

Improved Predictability

Surgical Paradigm

MAPPING CATEGORIES TO THE SURGICAL VALUE CHAIN

Laparoscopy

Manual Control

Robotic Surgery


Robotic Precision and Control

Digital Laparoscopy

Advanced Sensing, Digital Insights


Performance-Guided Surgery

Intelligent Preparation, Perceptive Real-Time Guidance




Unlocking Clinical Intelligence

THE SURGICAL ASSURANCE FRAMEWORK



Our Path to Market Leadership

Senhance



Robust Digital Laparoscopy platform built on the fundamentals of MIS

Intelligent Surgical Unit™ (ISU™)



Digital Platform capable of machine vision and augmented intelligence to enable real-time surgical analytics


Performance-Guided Surgery



Clinical Intelligence to unlock superior outcomes with surgery

Global organizational footprint and installed base

Continued focus and targeted investments that drive innovation to create the future of surgery



Key Operational Accomplishments

2020 - 2021 Operational Highlights

SIGNIFICANT OPERATIONAL PROGRESS IN 2020 - 2021

- Ten Senhance lease agreements signed, 9 clinical programs initiated and completed ~1,450+ cases in 2020
- Received FDA clearance, CE Mark and completed first surgical procedures using Augmented Intelligence(AI) and machine vision system, Intelligent Surgical Unit (ISU)
- Received CE Mark and completed first surgical procedures for pediatric use of Senhance with 3 mm instruments in Europe
- Received Russia Regulatory Approval for the Senhance system
- Received FDA clearance for General Surgery indication expansion
- Established Asia Pacific training center at Saitama Medical University International Medical Center in Japan and second European training center at Amsterdam Skills Centre in the Netherlands



2020 Financials (unaudited)

 2020 Revenue ~ \$3.0 - \$3.2 million

 December 31, 2020 Balance Sheet Highlights

- Cash & Restricted Cash ~ \$17.5 million
- Proforma Cash & Restricted Cash ~ \$173.4 million*
- Debt – None
- Cash Runway – into 2024

* The Company closed a Bought Deal Offering for gross proceeds of \$79.64 million and net proceeds of \$74.2 million on February 1, 2021, closed a Registered Direct Offering for gross proceeds of \$31.25 million and net proceeds of \$28.7 million on January 14, 2021, received proceeds of \$25.7 million on warrant exercises from January 1-25, 2021, and sold shares on the ATM for proceeds of \$27.3 million from January 1-12, 2021

Upcoming Milestones Support Operational Growth

CLINICAL ADOPTION, REGULATORY SUCCESS AND PEER REVIEWED PUBLICATIONS

- Regulatory Milestones (1H)
 - File FDA 510(k) for next generation ISU
 - File FDA 510(k) for articulating instruments
- Peer Reviewed Publications (1H)
 - Health-economic studies of Senhance, laparoscopy and robotics
 - Clinical performance
 - Operating room efficiency and surgeon ergonomics
- Continued momentum and penetration of ISU and usage of Augmented Intelligence and Machine Vision technology in the US, EU and Asia
- Further expansion of Pediatrics usage in Europe





ASENSUS
SURGICAL

